ELMD trades 78.5% below Wall Street's consensus target of $48.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ELMD achieves its forward estimates and maintains a stable P/E multiple of 22.3x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Electromed, Inc. (ELMD) has a Wall Street consensus price target of $48.50, based on estimates from 5 covering analysts. With the stock currently trading at $27.17, this represents a potential upside of +78.5%. The company has a market capitalization of $225M.
Analyst price targets range from a low of $47.00 to a high of $50.00, representing a 6% spread in expectations. The median target of $48.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ELMD trades at a trailing P/E of 20.9x and forward P/E of 22.3x. The forward PEG ratio of 1.74 indicates reasonable valuation for growth. Analysts expect EPS to grow -6.5% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $34.25, with bear and bull scenarios of $21.58 and $45.13 respectively. Model confidence stands at 53/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 INGNInogen, Inc. | $163M | $6.03 | $26.00 | +331.2% | Buy | — | 11 |
 LNTHLantheus Holdings, Inc. | $6.6B | $100.61 | $102.65 | +2.0% | Buy | 18.8x | 19 |
 LUNGPulmonx Corporation | $108M | $2.56 | $5.00 | +95.3% | Buy | — | 9 |
 SPXCSPX Technologies, Inc. | $7.1B | $142.71 | $246.67 | +72.8% | Buy | 17.0x | 12 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 PHGKoninklijke Philips N.V. | $29.7B | $30.35 | — | — | Hold | 18.2x | 22 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 ITRIItron, Inc. | $4.3B | $98.44 | $134.33 | +36.5% | Hold | 14.6x | 38 |
 PRPHProPhase Labs, Inc. | $72884 | $0.01 | — | — | — | — | — |
Quick answers to the most common questions about buying ELMD stock.
The consensus Wall Street price target for ELMD is $48.5, representing 78.5% upside from the current price of $27.17. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ELMD has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $48.5 implies 78.5% upside from current levels.
ELMD trades at a forward P/E of 22.3309x, representing a moderate valuation. With analysts targeting $48.5 (78.5% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $50 for ELMD, while the most conservative target is $47. The consensus of $48.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $45 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ELMD is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ELMD stock forecast based on 5 Wall Street analysts shows a consensus price target of $48.5, with estimates ranging from $47 (bear case) to $50 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $34, with bear/bull scenarios of $22/$45.
Our quantitative valuation model calculates ELMD's fair value at $34 (base case), with a bear case of $22 and bull case of $45. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 53/100.
ELMD trades at a forward P/E ratio of 22.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ELMD, with a "Buy" consensus rating and $48.5 price target (78.5% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ELMD analyst price targets range from $47 to $50, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $48.5 consensus represents the middle ground. Our model's $22-$45 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.